UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 356

Sortiert nach

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

Clinical cancer research, 2017-07, Vol.23 (14), p.3711-3720

2017

Volltextzugriff (PDF)

American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility

Journal of clinical oncology, 2015-11, Vol.33 (31), p.3660-3667

2015

Volltextzugriff (PDF)

Helping Patients Understand and Cope with BRCA Mutations

Current oncology reports, 2022-06, Vol.24 (6), p.733-740

2022

Volltextzugriff (PDF)

Hematologic malignancies in Li–Fraumeni syndrome: A case report

American journal of medical genetics. Part A, 2024-07, Vol.194 (7), p.e63573-n/a

2024

Volltextzugriff (PDF)

Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer

Cancer research (Chicago, Ill.), 2015-11, Vol.75 (22), p.4863-4875

2015

Volltextzugriff (PDF)

Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

Clinical cancer research, 2011-03, Vol.17 (5), p.1082-1089

2011

Volltextzugriff (PDF)

Validation of a personalized risk prediction model for contralateral breast cancer

Breast cancer research and treatment, 2018-07, Vol.170 (2), p.415-423

2018

Volltextzugriff (PDF)

Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing

Annals of surgical oncology, 2020-11, Vol.27 (12), p.4613-4621

2020

Volltextzugriff (PDF)

ASO Visual Abstract: Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing

Annals of surgical oncology, 2023-03, Vol.30 (3), p.1669-1670

2023

Volltextzugriff (PDF)

Increasing referral of at‐risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center

Cancer, 2022-01, Vol.128 (1), p.94-102

2022

Volltextzugriff (PDF)

Use of breast surveillance between women with pathogenic variants and variants of uncertain significance in breast cancer susceptibility genes

Cancer, 2022-10, Vol.128 (20), p.3709-3717

2022

Volltextzugriff (PDF)

Contralateral Prophylactic Mastectomy among Women with Pathogenic Variants in BRCA1/2: Overall Survival, Racial, and Ethnic Differences

The breast journal, 2022, Vol.2022, p.1447545-9

2022

Volltextzugriff (PDF)

Cancer Incidence in First‐ and Second‐Degree Relatives of BRCA1 and BRCA2 Mutation Carriers

The oncologist (Dayton, Ohio), 2016-07, Vol.21 (7), p.869-874

2016

Volltextzugriff (PDF)

Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes

Cancer, 2021-10, Vol.127 (19), p.3605-3613

2021

Volltextzugriff (PDF)

Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing

Annals of surgical oncology, 2023-03, Vol.30 (3), p.1663-1668

2023

Volltextzugriff (PDF)

Survival outcomes of patients with HER2/neu‐positive breast cancer with germline BRCA mutations

Cancer, 2024-05, Vol.130 (9), p.1600-1608

2024

Volltextzugriff (PDF)

Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations

Breast cancer research and treatment, 2018-07, Vol.170 (1), p.101-109

2018

Volltextzugriff (PDF)

Clinical implications of breast cancer tumor genomic testing

The breast journal, 2020-08, Vol.26 (8), p.1565-1571

2020

Volltextzugriff (PDF)

Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline Q and A

JCO global oncology, 2024-01, Vol.10 (10), p.e2300411-e2300411

2024

Volltextzugriff (PDF)

Health care professionals’ attitudes toward cancer gene panel testing

The breast journal, 2021-05, Vol.27 (5), p.499-500

2021

Volltextzugriff (PDF)

Multigene panel testing results in patients with multiple breast cancer primaries

The breast journal, 2020-07, Vol.26 (7), p.1337-1342

2020

Volltextzugriff (PDF)

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)

Clinical cancer research, 2021-09, Vol.27 (18), p.4983-4993

2021

Volltextzugriff (PDF)

Long-Term Adaptation Among Adolescent and Young Adult Children to Familial Cancer Risk

Pediatrics (Evanston), 2022-08, Vol.150 (2), p.1

2022

Volltextzugriff (PDF)

Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation

Clinical cancer research, 2022-09, Vol.28 (17), p.3669-3676

2022

Volltextzugriff (PDF)

1 – 25 von 356

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(331)
Mit Volltextzugriff
(333)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(64)
Cancer
(41)
Cancer Research
(35)
Breast Cancer Research And Treatment
(29)
Clinical Cancer Research
(18)
Cancer Prevention Research
(17)
The Breast Journal
(14)
The breast Journal
(11)
Annals Of Surgical Oncology
(8)
The Oncologist
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility

Helping Patients Understand and Cope with BRCA Mutations

Hematologic malignancies in Li–Fraumeni syndrome: A case report

Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer

Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

Validation of a personalized risk prediction model for contralateral breast cancer

Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing

ASO Visual Abstract: Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing

Increasing referral of at‐risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center

Use of breast surveillance between women with pathogenic variants and variants of uncertain significance in breast cancer susceptibility genes

Contralateral Prophylactic Mastectomy among Women with Pathogenic Variants in BRCA1/2: Overall Survival, Racial, and Ethnic Differences

Cancer Incidence in First‐ and Second‐Degree Relatives of BRCA1 and BRCA2 Mutation Carriers

Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes

Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing

Survival outcomes of patients with HER2/neu‐positive breast cancer with germline BRCA mutations

Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations

Clinical implications of breast cancer tumor genomic testing

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1 - or BRCA2 -Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline Q and A

Health care professionals’ attitudes toward cancer gene panel testing

Multigene panel testing results in patients with multiple breast cancer primaries

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)

Long-Term Adaptation Among Adolescent and Young Adult Children to Familial Cancer Risk

Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation

Aktive Filter

Suchergebnisse filtern